KBR and HJF bags contract to aid military neuroscience research

KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE

WHO issues warning on the surge of new age gateway devices among children

Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use

Roche to acquire Carmot Therapeutics for US$ 2.7 billion

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric

Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

GenNext & SCIEX to co-market HOS workflow for biopharmaceutical research

The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics

Amgen settles with FTC over US$28 billion deal

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor